| Size | Price | |
|---|---|---|
| 500mg | ||
| 1g | ||
| Other Sizes |
| ln Vitro |
AGB-374 (0.12–10 μM; 6 days) exhibited significant synergistic cytotoxicity with JR4 or JR5 in HCT116, MIA PaCa-2, and PANC-1 cells [1]. AGB-374 (10 μM; 24 hours) downregulated the expression level of NDUFS7 protein in HCT116 cells [1].
|
|---|---|
| ln Vivo |
AGB-374 (25 mg/kg; orally; 3 times/day for 48 hours; for 15 consecutive days) significantly reduced the MYC protein level in CT26 colon tumors in BALB/c mice, inhibited colon tumor growth, and did not cause systemic toxicity [1].
|
| Cell Assay |
Cytotoxicity assay [1] Cell Types: HCT116, MIA PaCa-2 and PANC-1 cells Test concentrations: 0, 0.12, 0.37, 1.1, 3.3, 10 μM
Incubation Duration: 6 days Experimental Results: Significant synergistic cytotoxicity was observed in HCT116 cells with JR4 or JR5. Western Blot Analysis [1] Cell Types: HCT116 cells Tested Concentrations: 10 μM Incubation Duration: 24 hours Experimental Results: The level of NDUFS7 protein in HCT116 cells was reduced. |
| Animal Protocol |
Animal/Disease Models:BALB/c (female, 8-10 weeks old, subcutaneously implanted with CT26 mouse colon cancer cells) [1]
Doses: 25 mg/kg Route of Administration: Oral; three times daily for 48 hours for 15 days Experimental Results: The mean relative level of MYC/GAPDH in tumor tissue was reduced to 0.38 compared to the control group (mean 0.96). The level of CTR1 protein in tumors was reduced in the treatment group compared to the control group, but the difference was not statistically significant. Tumor growth was significantly delayed. The mean final tumor weight was significantly reduced. No obvious toxic reactions, behavioral changes or weight changes were observed throughout the study. Histopathological analysis showed no microscopic or morphological abnormalities in the liver, heart, kidneys and spleen. The level of MYC protein in tumor tissue was reduced compared to the control group. |
| References |
| Molecular Formula |
C19H27CLF3N3O5S2
|
|---|---|
| Molecular Weight |
534.01
|
| Appearance |
Typically exists as solids at room temperature
|
| SMILES |
CC(S(=O)(C1=CC=C(C(F)=C1)S(=O)(N2CCN[C@H](C2)C(N3CCC(F)(CC3)F)=O)=O)=O)C.Cl
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.8726 mL | 9.3631 mL | 18.7262 mL | |
| 5 mM | 0.3745 mL | 1.8726 mL | 3.7452 mL | |
| 10 mM | 0.1873 mL | 0.9363 mL | 1.8726 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
